Asundexian Phase 3 OCEANIC-STROKE Trial: Factor XIa Inhibitor Achieves 40% Stroke Reduction with 70% Less Bleeding Than Warfarin in 12,000 AF Patients

What Is Asundexian and How Does Factor XIa Inhibition Work?

Asundexian (BAY 2433334, developed by Bayer) belongs to a new class of anticoagulants that target Factor XIa, a serine protease in the intrinsic (contact activation) pathway of coagulation. Factor XI occupies a unique position in the coagulation cascade: it amplifies thrombin generation through a positive feedback loop (thrombin activates Factor XI, which activates Factor IX, generating more thrombin via the tenase complex) that is critical for pathological thrombus growth in low-flow conditions such as the left atrial appendage in atrial fibrillation. However, Factor XI is largely dispensable for hemostasis — the initial burst of thrombin generated by the tissue factor/Factor VIIa extrinsic pathway is sufficient to form a hemostatic plug at wound sites.

This biological insight derives from the observation that individuals with severe Factor XI deficiency (hemophilia C) have only a mild bleeding diathesis, primarily limited to surgical or trauma-related bleeding, and appear to be protected from venous thromboembolism and ischemic stroke. Epidemiological studies of Factor XI-deficient populations, including Ashkenazi Jewish cohorts where the condition is prevalent (affecting approximately 8% as carriers), have shown lower rates of deep vein thrombosis, pulmonary embolism, and ischemic stroke compared to the general population. Asundexian was designed to exploit this therapeutic window by selectively inhibiting Factor XIa with high selectivity over other coagulation serine proteases, including thrombin, Factor Xa, and Factor IXa.

What Happened in the OCEANIC Clinical Trials?

Asundexian advanced to Phase 3 testing based on encouraging Phase 2 data, including the PACIFIC-STROKE trial, which tested asundexian in patients with recent non-cardioembolic ischemic stroke or transient ischemic attack. The PACIFIC-STROKE trial provided initial safety signals suggesting that Factor XIa inhibition could reduce bleeding risk compared to standard anticoagulation, though efficacy results for preventing recurrent stroke were not statistically significant.

Bayer subsequently launched two major Phase 3 trials: OCEANIC-STROKE, which tested asundexian for secondary stroke prevention, and OCEANIC-AF, a large trial comparing asundexian to apixaban in patients with atrial fibrillation. However, both programs were discontinued. OCEANIC-AF was stopped in late 2023 after an independent Data Safety Monitoring Board (DSMB) recommended termination because asundexian was inferior to apixaban in preventing stroke and systemic embolism, without demonstrating the expected significant bleeding advantage. OCEANIC-STROKE was also terminated for insufficient efficacy.

The failure of these trials was a significant setback for Bayer's cardiovascular pipeline and raised questions about whether oral small-molecule Factor XIa inhibitors can achieve sufficient target inhibition to prevent pathological thrombosis. However, experts noted that the biological rationale for targeting Factor XI remains sound, and the results may reflect drug-specific limitations rather than a failure of the entire therapeutic concept. Some researchers have suggested that complete or near-complete Factor XI inhibition may be required for clinical benefit — a level that may be more achievable with antibody-based approaches than small molecules.

Are Other Factor XIa Inhibitors Still Being Developed?

The Factor XI/XIa inhibitor class extends well beyond asundexian. Milvexian, an oral Factor XIa inhibitor developed jointly by Bristol-Myers Squibb and Janssen, showed encouraging dose-dependent reductions in ischemic stroke in the Phase 2 AXIOMATIC-SSP trial in patients with recent stroke or TIA. Phase 3 trials (the LIBREXIA program) were subsequently initiated to test milvexian in larger populations for both secondary stroke prevention and atrial fibrillation. Researchers noted that milvexian may achieve more complete Factor XIa inhibition at therapeutic doses compared to asundexian, which could be clinically relevant.

Abelacimab, developed by Anthos Therapeutics, takes a different approach as a monoclonal antibody that binds to Factor XI and prevents its activation. The antibody approach offers the advantage of near-complete Factor XI inhibition with once-monthly subcutaneous injection. In Phase 2 trials, abelacimab demonstrated dramatic reductions in venous thromboembolism after knee replacement surgery and showed promising bleeding safety profiles. The AZALEA-TIMI 71 trial tested abelacimab in atrial fibrillation patients, though results of this program also faced challenges. The class remains an active area of investigation, with pharmaceutical companies and academic researchers continuing to refine dosing strategies and patient selection to realize the therapeutic promise of Factor XIa inhibition.

What Would Successful Factor XIa Inhibition Mean for Patients?

Current standard-of-care anticoagulants for atrial fibrillation — including direct oral anticoagulants (DOACs) such as apixaban (Eliquis), rivaroxaban (Xarelto), edoxaban (Savaysa), and dabigatran (Pradaxa) — have substantially improved stroke prevention compared to warfarin, with the landmark RE-LY, ROCKET AF, ARISTOTLE, and ENGAGE AF-TIMI 48 trials demonstrating approximately 19% better stroke reduction and modestly lower bleeding rates. However, DOACs still carry meaningful bleeding risk, particularly for intracranial hemorrhage and gastrointestinal bleeding, which limits their use in vulnerable populations.

The patient populations that would benefit most from a successful Factor XIa inhibitor include elderly patients with high fall risk and bleeding susceptibility, patients with chronic kidney disease (where DOAC dosing is complicated by renal clearance), patients requiring concomitant antiplatelet therapy after coronary stenting (dual pathway therapy), and those who have experienced bleeding complications on DOACs. Additionally, many AF patients worldwide — particularly in lower-income settings — remain on warfarin with its requirement for regular INR monitoring, dietary restrictions, and narrow therapeutic window. A safer anticoagulant with a wide therapeutic window could expand access to effective stroke prevention. While asundexian did not fulfill this promise, the ongoing clinical trials of other Factor XI/XIa inhibitors continue to pursue what many cardiologists and hematologists consider the most important unmet need in anticoagulation therapy.